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ABSTRACT
Introduction: The present study assessed the
efficacy of initial basal-supported oral therapy
(BOT) with sitagliptin for achievement of
glycemic control and subsequent switching
from BOT to sitagliptin-based oral therapy.
Methods: Nineteen recently diagnosed type 2
diabetic patients who had received no
antidiabetic medication in the previous 2 years
were sequentially examined for the 24-week
study. Patients were initially treated with a
combination of insulin glargine and
sitagliptin. Sitagliptin was initiated and
maintained at a dose of 50 mg/day, and
insulin glargine was started at a dose of 4 U at
bedtime and adjusted if needed.
Results: During the 24-week treatment period,
12 patients (63%) achieved HbA1c levels \7%
(mean BOT duration 13.7 ± 5.6 weeks) and
switched from BOT to sitagliptin
monotherapy or in combination with
metformin (achievers). The remaining seven
patients (37%) failed to achieve HbA1c levels
\7% (non-achievers) and continued on BOT.
Both FPG and HbA1c in achievers significantly
dropped at 4, 8, 12 and 24 weeks from baseline,
while those in non-achievers significantly
decreased at 12 and 24 weeks from baseline,
but failed to reach target glycemic control.
There were statistically significant differences
in FPG at 4, 8, 12 and 24 weeks and in HbA1c
at 8, 12 and 24 weeks between achievers and
non-achievers. Body weight and BMI in
achievers were significantly reduced at 12 and
24 weeks, but those in non-achievers did not
change significantly. Dosage of concomitant
insulin during BOT was significantly lower in
achievers compared to non-achievers. Non-
achievers had a similar CPI, a measure of
insulin secretion capacity, to achievers, but
significantly showed an insulin resistance
index (value of 20/[fasting CPR 9 FPG]), in
comparison to achievers.
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Conclusion: Initiating BOT with sitagliptin
followed by sitagliptin-based oral therapy is a
useful option in untreated and poorly
controlled patients with type 2 diabetes.
Keywords: Basal-supported oral therapy (BOT);
Sitagliptin; Type 2 diabetes
INTRODUCTION
Short-term intensive insulin therapy prescribed
early on in the course of type 2 diabetes can
improve b-cell function and insulin resistance
by eliminating glucotoxicity and lead to drug-
free glycemic remission for up to 2 years [1, 2].
However, intensive insulin therapy is not
generally suitable for outpatients who are
often unable to undergo multiple insulin
injections; as a result many patients are
prescribed oral hypoglycemic agents (OHAs)
when they are no longer in glycemic
remission. Basal-supported oral therapy (BOT),
comprising a basal insulin and OHAs, is an
alternative option in this clinical setting [3–5].
However, conventional BOT using
sulfonylureas (SUs) mainly controls fasting
plasma glucose (FPG) and does not necessarily
correct post-prandial glycemia; as a
consequence, adequate glycemic control is not
always achieved and frequent hypoglycemic
episodes may occur [6]. Thus, achieving target
glycemic control using conventional BOT is
limited.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are
used in clinical practice for the treatment of
type 2 diabetes [7, 8]. These agents have an
advantage over SUs as they regulate insulin
secretion in a glucose-dependent manner [9,
10], thereby minimizing the risk of
hypoglycemia [11] and reducing glycemic
fluctuations [12, 13]. A few studies evaluating
BOT using DPP-4 inhibitors have demonstrated
a glucose-lowering effect when used in
conjunction with ongoing insulin therapy in
patients with type 2 diabetes [14–16]. The aim
of the present study was to evaluate whether
starting BOT with sitagliptin, a DPP-4 inhibitor,
achieves adequate glycemic control and allows




Patients aged between 30 and 70 years were
enrolled in the study if they had a new or recent
diagnosis of type 2 diabetes, had not been
treated with an antidiabetic agent in the
previous 2 years, and had poor glycemic
control (hemoglobin A1c [HbA1c] C9.0%).
Patients were excluded if they had type 1
diabetes, chronic liver disease, advanced
kidney disease, were taking corticosteroids, or
were diagnosed with diabetic ketoacidosis.
Treatment
Patients were educated in diet therapy
[25 kcal 9 ideal body weight (kg) per day] by a
dietician and instructed to take 12,000 steps per
day as exercise, according to the Japanese
treatment guide for diabetes [17]. Adherence
to diet and exercise therapy was evaluated by
the proportion of patients attaining at least 80%
of the instructed levels using self-dietary records
and pedometer, respectively.
Patients were treated with a combination of
sitagliptin and insulin glargine for 24 weeks.
Sitagliptin was initiated and maintained at a
dose of 50 mg/day, and insulin glargine was
initiated at a dose of 4 U at bedtime and
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adjusted if needed at monthly clinic visit
(increased by 1 unit when FPG [180 mg/dL,
and decreased by 1 unit when FPG\90 mg/dL).
Patients who achieved an HbA1c of\7% during
the 24-week treatment period were referred to as
achievers and discontinued their basal insulin
therapy. They were then maintained on
sitagliptin (50 mg/day) monotherapy or on a
combination of sitagliptin with metformin
(500–1,500 mg/day). Patients who did not
achieve an HbA1c of \7% (non-achievers)
continued on BOT throughout the 24-week
treatment period.
Study End Points
The primary end point was the proportion of
patients who achieved an HbA1c \7.0% during
BOT and discontinued basal insulin during the
24-week treatment period. Secondary end
points were changes of FPG and HbA1c from
baseline in achievers and non-achievers during
the 24-week study period. C-peptide index
(CPI), a measure of insulin secretion capacity
[18], was calculated at week 12 using the
following formula: [100 9 fasting C-peptide
immunoreactivity (CPR) (ng/mL)]/[FPG (mg/
dL)]. In addition, 20/[fasting CPR (mmol/
L) 9 FPG (mmol/L)], a potential index of
insulin resistance, was also calculated at week
12 [18]. Lower value of this index indicates
being more insulin resistant. HbA1c levels were
determined using high-performance liquid
chromatography with an automated AH-8280
analyzer (ARKRAY, Kyoto, Japan) at every
clinical visit.
Safety Assessment
Hypoglycemic episodes were counted by
documentation of any hypoglycemic episodes
and any symptoms derived from hypoglycemia
based on patients’ reports.
Statistical Analysis
All statistical analyses were performed using the
StatView software package version 5.0 (Abacus
Concept, Berkeley, CA). Changes in FPG and
HbA1c at 4, 8, 12, and 24 weeks versus baseline
were evaluated using ANOVA followed by
Bonferroni’s test. Unpaired t test was used to
compare the parameters between achievers and
non-achievers. A p value of \0.05 was
considered statistically significant. Data are
presented as mean (±standard deviation [SD]).
Ethics Statement
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
RESULTS
A total of 22 patients were enrolled in the study
and 19 of the participants completed the study
protocol. Patient baseline characteristics are
summarized in Table 1.
Efficacy
During the 24-week treatment period, 12
patients (63.2%) achieved an HbA1c \7%
using initial BOT (achievers).The mean time to
achieve HbA1c\7.0% among the achievers was
13.7 ± 5.6 weeks. All achievers switched from
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BOT to sitagliptin monotherapy or in
combination with metformin during the study
period. The remaining seven patients (36.8%)
failed to achieve HbA1c levels \7% during
24 weeks of treatment (non-achievers).
Rates of adherence to diet and exercise were
higher in achievers (diet 75%; exercise 67%)
than in non-achievers (diet 43%; exercise 29%).
Both FPG and HbA1c in achievers
significantly dropped at 4, 8, 12 and 24 weeks
from baseline, while those in non-achievers
significantly decreased at 12 and 24 weeks from
baseline, but failed to reach at target glycemic
control (Fig. 1). There were statistically
significant differences in FPG at 4, 8, 12 and
24 weeks and in HbA1c at 8, 12 and 24 weeks
between achievers and non-achievers.
The achievers experienced a significant
reduction in body weight and BMI at 12 and
24 weeks versus baseline, while the non-
achievers did not (Table 2). The insulin
requirement for achievers (3.8 ± 0.8 U/day)
was significantly lower than that for non-
achievers (7.3 ± 3.3 U/day) during BOT.
Concomitant metformin dosage was
significantly lower in achievers (500 ± 0 mg/
day; n = 2) than in non-achievers
(1,050 ± 450 mg/day; n = 5). There was no
significant difference in CPI between achievers
and non-achievers; however, non-achievers
showed a significant insulin resistance index
(value of 20/[fasting CPR 9 FPG]) compared to
achievers.
Table 1 Baseline clinical characteristics of the study
population
Age (years)a 48.7 ± 8.3
Sex: male/female (n) 16/3
Duration of diabetes (years)a 3.1 ± 2.3
Body weight (kg) 78.2 ± 16.0
BMI (kg/m2) 26.9 ± 5.1
FPG (mg/dL) 215 ± 48
HbA1c (%)a 11.0 ± 1.5
Triglyceride (mg/dL) 160 ± 77
HDL-C (mg/dL)a 50 ± 11
LDL-C (mg/dL)a 111 ± 29
Hypertension, n (%) 6 (31.5%)
Dyslipidemia, n (%) 9 (47.4%)
BMI body mass index, FPG fasting plasma glucose, LDL-
C low-density lipoprotein cholesterol, HDL-C high-
density lipoprotein cholesterol, HbA1c hemoglobin A1c
a Continuous data are means (SD)
Fig. 1 a Change in fasting plasma glucose (FPG) and
b hemoglobin A1c (HbA1c) with time among achievers
and non-achievers during the 24-week study period.
Achievers: patients who achieved HbA1c of \7.0% and
switched from BOT to sitagliptin-based oral therapy
during the 24-week study period. Non-achievers: patients
who failed to achieve HbA1c of\7.0% and continued on
BOT during the 24-week study period. *p\0.05,
**p\0.01 (vs. week 0) #p\0.05, ##p\0.01 (achievers
vs. non-achievers)
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Safety
Two patients in the achiever group and one
patient in the non-achiever group experienced
hypoglycemia; there were no cases of severe
hypoglycemia.
No patients had to discontinue the present
protocol because of other side effects.
DISCUSSION
The current study demonstrated that initiating
BOT with sitagliptin successfully improved
glycemic control and allowed patients to
switch from BOT to sitagliptin monotherapy
or combination therapy, maintaining adequate
glycemic control during a 24-week period in
untreated patients with type 2 diabetes.
BOT is often prescribed for outpatients
because once daily injection is more acceptable
than multiple insulin injections. The benefit of
BOT in clinical practice has been described
previously [3–5]. BOT has traditionally
comprised an SU plus a long-acting insulin
analog [5]. However, one of the biggest
problems associated with conventional BOT is
postprandial hyperglycemia while FPG is within
normal range. DPP-4 inhibitors, as monotherapy
or combination therapy, have several advantages
over SUs, since these agents enhance insulin
secretion in a glucose-dependent manner and
suppress glucagon secretion [9, 10].
In the current study, 12 patients (63.2%)
achieved HbA1c \7% using initial BOT, and
subsequently discontinued basal insulin. These
achievers showed a significant decrease in
HbA1c at 4, 8, 12 and 24 weeks versus
baseline, and versus non-achievers at 8, 12 and
24 weeks. The basal insulin dose was relatively
low and the duration of BOT was short to
achieve target glycemic control. In contrast, the
remaining seven patients (36.8%) failed to
achieve a target HbA1c \7% during the
24-week treatment period, although in
common with the achievers they adhered to
their instructed insulin injection. It is reported
that insulin therapy is usually required in
Japanese type 2 diabetic patients with a CPI
(insulin secretion capacity) lower than 0.8 [18].
CPI was measured at 12 weeks because





Sex: male/female (n) 11/1 5/2
Age (years)a 49.6 ± 9.6 47.1 ± 5.8
Duration of
diabetes (years)a
2.9 ± 2.0 3.6 ± 2.7
Body weight (kg) 78.1 ± 13.9 78.3 ± 20.4
D Body weight (kg)a
12 weeks -4.2 ± 3.7* -0.4 ± 1.4
24 weeks -6.6 ± 5.2** 0.7 ± 2.2
BMI (kg/m2) 26.3 ± 3.8 28.0 ± 7.0
D BMI (kg/m2)
12 weeks -1.8 ± 1.3** 0.1 ± 0.9
24 weeks -1.8 ± 1.7** 0.3 ± 0.9
Insulin dose during
BOT (U/day)
3.8 ± 0.8** 7.3 ± 3.3
CPI at 12 weeks 1.7 ± 0.5 1.4 ± 0.6
20/(FPG 9 CPR)
at 12 weeks
6.2 ± 2.1* 3.8 ± 1.3
BOT basal-supported oral therapy, CPR C-peptide
immunoreactivity, CPI C-peptide index, FPG fasting
plasma glucose
* p\0.05, ** p\0.01 by unpaired t test (achievers vs. non-
achievers)
a Continuous data are means (SD). D Body weight:
change from baseline, D BMI: change from baseline
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glucotoxicity might have influenced this index
at baseline. In comparison to the achievers, the
non-achievers had a similar CPI, but a
significantly lower 20/[fasting CPR 9 FPG]
level, a possible marker of insulin resistance
[19] at 12 weeks. Lower value of this index
indicates being more insulin resistant. Body
weight and BMI in non-achievers were not
significantly reduced from baseline, probably
because these patients did not strictly adhere to
diet and exercise therapy. These results suggest
that insulin resistance was not sufficiently
improved to allow non-achievers to
discontinue basal insulin.
In the Add-on Lantus to Oral Hypoglycemic
Agents (ALOHA) study in insulin-naı¨ve 3,515
Japanese patients starting insulin glargine
(mean dose 8.5 U/day) plus OHAs, mainly SUs,
15.5% of participants achieved HbA1c\7.0% at
24 weeks, whereas 84.5% of participants did
not. In such a study, a shorter duration of
diabetes (\1 year) and lower HbA1c (\8.5%) at
baseline were significantly associated with a
higher rate of achieving target HbA1c (\7.0%)
[20]. Previous BOT trials [14–16] with DPP-4
inhibitors added to ongoing insulin therapy in
patients with type 2 diabetes have
demonstrated a significant glucose-lowering
effect; however, the background of previous
studies [14–16] where duration of diabetes was
over 10 years, daily insulin dose exceeded 15 U/
day and concomitant OHAs were frequently
used is quite different from the current study.
Recently, Harashima et al. [21] have
demonstrated in a 52-week study of ongoing
BOT with SUs that replacement of basal insulin
with sitagliptin was associated with a decrease
in HbA1c level (\7.0%) in 67.4% of patients
with a mean diabetes duration of 12.1 years,
while 32.6% of subjects with a longer duration
of diabetes (*18.9 years) and receiving higher
doses of concomitant SUs could not replace
basal insulin by sitagliptin. Taken together, the
efficacy of BOT in type 2 diabetes patients may
be related to several factors of duration of
diabetes, pre-treatment or insulin resistance.
This study has some limitations. First, this
was a single arm, single center study involving a
small sample of patients. It was unable to
compare the efficacy and convenience of
initial treatments between the current study of
BOT with sitagliptin and other therapies by BOT
with SU or multiple insulin injection regimen.
Second, the study findings cannot be
generalized to patients with type 2 diabetes
who would not meet the study inclusion
criteria, i.e., drug-naı¨ve patients with recently
diagnosed, poorly controlled type 2 diabetes.
Third, the titration of basal insulin and
adherence to diet and exercise may have been
insufficient for the non-achievers. On this basis,
a large prospective study is needed to validate
the findings of the current study.
CONCLUSION
The current study showed that initial
introduction of BOT with sitagliptin was
effective for achievement of glycemic control
and subsequent switching from BOT to DPP-IV
inhibitor-based therapy in recent onset and
untreated patients with type 2 diabetes.
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